TriangleSR-8541A (NCT06589440)
SR-8541A trial for Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) (NCT06589440). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with unresectable, metastatic microsatellite-stable colorectal adenocarcinoma after at least one chemotherapy regimen. Prior checkpoint immunotherapy is excluded; groups include patients with and without active liver metastases.
The idea: oral SR-8541A blocks ENPP1, aiming to preserve signals that activate anticancer immunity. Intravenous botensilimab and balstilimab block CTLA-4 and PD-1 immune brakes. Researchers first escalate doses, then study larger groups for safety and tumor response. Screening tumor tissue is required; post-treatment tissue is optional.
This phase 2 study plans 70 patients. Stingray Therapeutics sponsors it; six US sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.